Symbicort in Chronic Obstruktive Pulmonary Disease
Completed
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Registration Number
- NCT00612976
- Lead Sponsor
- AstraZeneca
- Brief Summary
Under daily routine conditions and without any intervention by the sponsor regarding the selection of subjects, diagnostic procedures, therapeutic decisions (medicinal and non- medicinal therapy, dose, duration, etc.), routine assessments, the participating physicians (i.e.general practitioners and internists) are asked to document relevant data related to the budesonide/formoterole therapy in patients with COPD.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 18014
Inclusion Criteria
- Patients with COPD treated with budesonide/formoterol
Read More
Exclusion Criteria
- limitiations; possible risks; warnings; contraindications mentioned in the SPC.
Read More
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method efficacy and tolerability of budesonide /formoterole in subjects with COPD who are treated by general practitioners and internists. change of a quality of life score compared to baseline by using CRQ, stratified by present therapy and severity of COPD; incidence of the occurrence of unknown, unexpected and/or rarely occurring adverse events AE under outpatient medical care conditions
- Secondary Outcome Measures
Name Time Method to get further insight into the details of the use , dosage scheme and duration of treatment with budesonide /formoterol in this population